Need help finding what you are looking for?
Contact Us
PUBLISHER: Roots Analysis | PRODUCT CODE: 1616889
PUBLISHER: Roots Analysis | PRODUCT CODE: 1616889
mRNA Synthesis and Manufacturing Market by Type of Product (Drug Substances and Drug Products ), Application Area, Therapeutic Area and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035
PUBLISHED:
PAGES: 170 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
MRNA SYNTHESIS AND MANUFACTURING MARKET: OVERVIEW
As per Roots Analysis, the global mRNA synthesis and manufacturing market is estimated to be worth USD 1.06 billion in the current year.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Product
- Drug Substances (APIs)
- Drug Products (FDFs)
Application Area
- mRNA-based Vaccines
- mRNA-based Therapeutics
Therapeutic Area
- Infectious Diseases
- Oncological Disorders
- Other Disorders
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
MRNA SYNTHESIS AND MANUFACTURING MARKET: GROWTH AND TRENDS
In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical reports demonstrating the efficacy of these platforms have been published in the last two years. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. However, the synthesis and manufacturing process of mRNA-based therapeutics / vaccines is complex and associated with several challenges. Production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Due to such operational and technical challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on contract service providers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and manufacturing services market to witness healthy growth.
MRNA SYNTHESIS AND MANUFACTURING MARKET: KEY INSIGHTS
The report delves into the current state of the mRNA synthesis and manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. The current market landscape features the presence of more than 35 companies that claim to offer services for custom synthesis of mRNA, across the world.
2. Various players offer different types of services for mRNA synthesis, based on the requirements of their clients; majority of the players prefer to use plasmid DNA as a starting material to synthesize mRNA.
3. Over 40 companies currently claim to offer contract manufacturing services for drug substance (mRNA) as well as drug product (mRNA-based vaccines and therapeutics), across various scales of operation.
4. Several firms (encompassing startups as well as well-established companies), with varying resources, have been actively involved in this domain; the majority of these firms have manufacturing facilities in Europe.
5. Presently, more than 95 kits (comprising of different components) are available in the market for the synthesis of customized mRNAs; notably, the majority of these have enzymes for cap modification of the mRNA.
6. mRNA synthesis kits carry out various reactions depending on the number of reagents in the kit; in addition, around 30% of the kits yield over 60 µg of mRNA per reaction.
7. In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their respective service offerings and comply with the evolving industry benchmarks.
8. In order to meet the rising demand, drug developers are steadily relying on CMOs for the production of mRNA; this approach not only offers a set of streamlined processes but also greater flexibility.
9. To cater to the rising demand for mRNA synthesis kits, companies are actively undertaking initiatives to integrate advanced features in their respective mRNA synthesis kit portfolios.
10. Both industry and non-industry players have forged strategic partnerships in the mRNA synthesis and manufacturing domain; notably, majority of the deals in this domain were manufacturing agreements.
11. Various mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and manufacturing service providers, to further augment their drug portfolio.
12. Several big pharma players have undertaken a variety of initiatives (partnerships, acquisitions, funding and expansion) for enhancing their mRNA-related portfolio and its therapeutic applicability.
13. Identifying the driving factors (that fuel advancement) as well as barriers (that slow down research progress) helps improve strategic planning and results in efficient operations in mRNA synthesis and manufacturing domain.
14. The opportunity within the mRNA synthesis and manufacturing market is likely to be well distributed across different types of product, application area, therapeutic area and key geographical regions.
MRNA SYNTHESIS AND MANUFACTURING MARKET: KEY SEGMENTS
Drug Substances (APIs) are Likely to Dominate the mRNA Synthesis and Manufacturing Market During the Forecast Period
Based on type of product, the market is segmented into drug substances (APIs) and drug products (FDFs). It is worth highlighting that majority of the current mRNA synthesis and manufacturing market is captured by bulk drug substances (APIs) and this trend is likely to remain the same in near future.
mRNA Therapeutics is the Fastest Growing Segment in the mRNA Synthesis and Manufacturing Market During the Forecast Period
Based on application area, the market is segmented into mRNA-based vaccines and mRNA-based therapeutics. It is worth highlighting that that majority of the current mRNA synthesis and manufacturing market is captured by mRNA vaccines.
Infectious Diseases Segment Accounts for the Largest Share for the mRNA Synthesis and Manufacturing Market
Based on therapeutic area, the market is segmented into infectious diseases, oncological disorders and other disorders. While infectious diseases account for a relatively higher market share, it is worth highlighting that oncological disorders segment is expected to witness substantial market growth in the coming years.
North America Holds the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that currently, North America captures majority of the mRNA synthesis and manufacturing market, and this trend is unlikely to change in the near future.
Example Players in the mRNA Synthesis and Manufacturing Market
- Aldevron
- Aurigene Pharmaceutical Services
- Biomay
- Curia
- eTheRNA
- Eurogentec
- Genscript
- Merck KGaA
- TriLink BioTechnologies
- Vernal Biosciences
- WuXi Biologics
- APExBIO
- CELLSCRIPT
- Enzynomics
- Jena Bioscience
- New England Biolabs
- Thermo Fisher Scientific
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
- Chief Executive Officer, eTheRNA
- Chief Commercial Officer, tebubio
- Business Development Manager, Canvax
- Team Leader, GC Pharma
MRNA SYNTHESIS AND MANUFACTURING MARKET: RESEARCH COVERAGE
- The report features an in-depth analysis of the mRNA synthesis and manufacturing market, focusing on key market segments, including type of product, application area, therapeutic area and key geographical regions.
- The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
- A comprehensive evaluation of mRNA custom synthesis service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), type of services offered (mRNA modification, mRNA purification, scale-up, process development and fill / finish), starting material (plasmid DNA, mRNA sequence and PCR fragments), structural modification (5' modification, 3' modification, ribonucleotide base modification and others), type of purification method (chromatography, electrophoresis, desalting / precipitation and others), application area (vaccine production, therapeutic production and others) and scale of operation (preclinical / research, clinical and commercial). Further, the chapter also features information on the length of the mRNA manufactured and mRNA production capacity of the stakeholders.
- A comprehensive competitive analysis of mRNA custom synthesis service providers (across key geographical regions), examining factors such as supplier strength and service strength.
- Thorough analysis of mRNA contract manufacturing service providers, detailing year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), location of manufacturing facilities, type of additional services offered (formulation development, analytical testing, process development, mRNA purification, fill / finish, scale-up, regulatory support and others) type of product manufactured (drug substances (APIs) and drug products (FDFs)) and scale of operation (preclinical / research, clinical and commercial).
- A comprehensive competitive analysis of mRNA contract manufacturing service providers (across key geographical regions), examining factors such as supplier strength and service portfolio strength.
- A detailed assessment of the current market landscape of mRNA synthesis kits based on several relevant parameters, such as kit components (enzyme mix, reagents, buffer and others), type of enzyme (capping enzyme and tailing enzyme), type of enzyme mix used (T7 polymerase, SP6 polymerase and T3 polymerase), mRNA component modified (cap, base and tail), number of reactions (5 reactions, 10 reactions, 15 reactions, 16 reactions, 20 reactions, 25 reactions, 48 reactions and 50 reactions), yield per reaction (less than 31µg, 31-60 µg, 61-90 µg and more than 90 µg), reaction run time (less than 61 minutes, 61-120 minutes and more than 120 minutes) and kit price (less than USD 500, USD 501-USD 700, USD 701-USD 900 USD, USD 901-USD 1,200 and more than 1,200 USD). In addition, the chapter provides a detailed analysis of mRNA synthesis kit providers, along with information on their year of establishment, company size (in terms of employees count), location of headquarters and most active players (in terms of number of mRNA synthesis kits offered).
- An insightful analysis of mRNA synthesis kits, based on supplier strength and product strength.
- In-depth profiles of key industry players in mRNA manufacturing market, focusing on company overviews, service portfolio, recent developments and an informed future outlook.
- Detailed profiles of the key mRNA synthesis kit providers, focusing on company overviews and mRNA synthesis kits portfolio.
- An analysis of partnerships established in this sector, since 2019, on the basis of several parameters, such as year of partnership, type of product, type of partner and most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
- A detailed evaluation of over 35 mRNA-based therapeutics / vaccines developers that are most likely to collaborate with mRNA contract manufacturing service providers. This analysis considers various relevant parameters, including developer strength (in terms of company's experience), company size, (in terms of number of employees), pipeline strength (based on the number of mRNA-based drugs in pipeline), highest phase of development, therapeutic area, route of administration and type of candidate being developed.
- Assessment of the various mRNA-focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative and therapeutic area.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this market?
- What is current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Product Code: RA100401
TABLE OF CONTENTS
1. PREFACE
- 1.1. mRNA Synthesis and mRNA Manufacturing Market
- 1.2. Market Share Insights
- 1.2.1. Market Segmentation Overview
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview of Major Currencies Affecting the Market
- 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
- 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 3.2.5.2. Potential Impact of Inflation on the Market Evolution
- 3.2.1. Time Period
4. EXECUTIVE SUMMARY
5. INTRODUCTION
- 5.1. Overview of mRNA
- 5.2. Structure of mRNA
- 5.3. Evolution of mRNA Vaccines
- 5.4. Steps involved in mRNA Synthesis
- 5.4.1. Chemical Synthesis of mRNA
- 5.4.2. In vitro Synthesis of mRNA
- 5.5. Applications of Chemical/ in vitro Synthesized mRNA
- 5.6. Challenges Associated with mRNA Synthesis
- 5.7. mRNA Contract Manufacturing
- 5.7.1. Commonly Outsourced mRNA Manufacturing Operations
- 5.7.2. Advantages of Outsourcing Manufacturing Operations
6. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE
- 6.1. mRNA Custom Synthesis Service Providers: Market Landscape
- 6.1.1. Analysis by Year of Establishment
- 6.1.2. Analysis by Company Size
- 6.1.3. Analysis by Location of Headquarters
- 6.1.4. Analysis by Type of Service Offered
- 6.1.5. Analysis by Starting Material
- 6.1.6. Analysis by Structural Modification
- 6.1.7. Analysis by Type of Purification Method
- 6.1.8. Analysis by Application Area
- 6.1.9. Analysis by Scale of Operation
- 6.1.10. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
- 6.1.11. mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity
7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
- 7.1. Chapter Overview
- 7.2. Assumptions and Methodology
- 7.3. Scoring Criteria
- 7.4. mRNA Custom Synthesis Service Providers: Company Competitiveness Analysis
- 7.4.1. mRNA Custom Synthesis Service Providers based in North America
- 7.4.2. mRNA Custom Synthesis Service Providers based in Europe
- 7.4.3. mRNA Custom Synthesis Service Providers based in Asia-Pacific
8. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
- 8.1. Chapter Overview
- 8.2. Detailed Company Profiles of Leading Service Providers
- 8.2.1. Aldevron
- 8.2.1.1. Company Overview
- 8.2.1.2. mRNA Custom Synthesis Service Portfolio
- 8.2.1.3. Recent Developments and Future Outlook
- 8.2.2. TriLink BioTechnologies
- 8.2.2.1. Company Overview
- 8.2.2.2. mRNA Custom Synthesis Service Portfolio
- 8.2.2.3. Recent Developments and Future Outlook
- 8.2.3. eTheRNA
- 8.2.3.1. Company Overview
- 8.2.3.2. mRNA Custom Synthesis Service Portfolio
- 8.2.3.3. Recent Developments and Future Outlook
- 8.2.1. Aldevron
- 8.3. Short Profiles of Other Prominent Custom Service Providers
- 8.3.1. Biomay
- 8.3.1.1. Company Overview
- 8.3.1.2. mRNA Custom Synthesis Service Portfolio
- 8.3.2. Genscript
- 8.3.2.1. Company Overview
- 8.3.2.2. mRNA Custom Synthesis Service Portfolio
- 8.3.3. Aurigene Pharmaceutical Services
- 8.3.3.1. Company Overview
- 8.3.3.2. mRNA Custom Synthesis Service Portfolio
- 8.3.1. Biomay
9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
- 9.1. mRNA Contract Manufacturing Service Providers: Market Landscape
- 9.1.1. Analysis by Year of Establishment
- 9.1.2. Analysis by Company Size
- 9.1.3. Analysis by Location of Headquarters (Region)
- 9.1.4. Analysis by Location of Headquarters (Country)
- 9.1.5. Analysis by Location of Manufacturing Facility
- 9.1.6. Analysis by Type of Additional Services
- 9.1.7. Analysis by Type of Product Manufactured
- 9.1.8. Analysis by Scale of Operation
10. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
- 10.1. Chapter Overview
- 10.2. Assumptions and Methodology
- 10.3. Scoring Criteria
- 10.4. mRNA Contract Manufacturing Service Providers: Company Competitiveness Analysis
- 10.4.1. mRNA Contract Manufacturing Service Providers based in North America
- 10.4.2. mRNA Contract Manufacturing Service Providers based in Europe
- 10.4.3. mRNA Contract Manufacturing Service Providers based in Asia-Pacific
11. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
- 11.1. Chapter Overview
- 11.2. Detailed Company Profiles of Leading Service Providers
- 11.2.1. Eurogentac
- 11.2.1.1. Company Overview
- 11.2.1.2. mRNA Contract Manufacturing Services Portfolio
- 11.2.1.3. Recent Developments and Future Outlook
- 11.2.2. WuXi Biologics
- 11.2.2.1. Company Overview
- 11.2.2.2. mRNA Contract Manufacturing Services Portfolio
- 11.2.2.3. Recent Developments and Future Outlook
- 11.2.3. Merck
- 11.2.3.1. Company Overview
- 11.2.3.2. mRNA Contract Manufacturing Services Portfolio
- 11.2.3.3. Recent Developments and Future Outlook
- 11.2.1. Eurogentac
- 11.3. Short Profiles of Other Prominent Service Providers
- 11.3.1. ST Pharm
- 11.3.1.1. Company Overview
- 11.3.1.2. mRNA Contract Manufacturing Services Portfolio
- 11.3.2. Vernal Biosciences
- 11.3.2.1. Company Overview
- 11.3.2.2. mRNA Contract Manufacturing Services Portfolio
- 11.3.3. Curia
- 11.3.3.1. Company Overview
- 11.3.3.2. mRNA Contract Manufacturing Services Portfolio
- 11.3.1. ST Pharm
12. mRNA SYNTHESIS KIT PROVIDERS: MARKET LANDSCAPE
- 12.1. mRNA Synthesis Kits: Market Landscape
- 12.1.1. Analysis by Kit Components
- 12.1.2. Analysis by Type of Enzyme
- 12.1.3. Analysis by Type of Enzyme Mix Used
- 12.1.4. Analysis by mRNA Component Modified
- 12.1.5. Analysis by Number of Reaction
- 12.1.6. Analysis by Yield per Reaction
- 12.1.7. Analysis by Reaction Run-time
- 12.1.8. Analysis by Kit Price
- 12.1.9. Most Active Players: Analysis by Number of Kits Offered
- 12.2. mRNA Synthesis Kits: Providers Landscape
- 12.2.1. Analysis by Year of Establishment
- 12.2.2. Analysis by Company Size
- 12.2.3. Analysis by Location of Headquarters
13. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
- 13.1. Chapter Overview
- 13.2. Assumptions and Methodology
- 13.3. Scoring Criteria
- 13.4. mRNA Synthesis Kits: Product Competitiveness Analysis
14. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS
- 14.1. Chapter Overview
- 14.2. Jena Biosciences
- 14.2.1. Company Overview
- 14.2.2. mRNA Synthesis Kits Portfolio
- 14.3. APExBIO
- 14.3.1. Company Overview
- 14.3.2. mRNA Synthesis Kits Portfolio
- 14.4. Thermo Fisher Scientific
- 14.4.1. Company Overview
- 14.4.2. mRNA Synthesis Kits Portfolio
- 14.5. CELLSCRIPT
- 14.5.1. Company Overview
- 14.5.2. mRNA Synthesis Kits Portfolio
- 14.6. New England Biolabs
- 14.6.1. Company Overview
- 14.6.2. mRNA Synthesis Kits Portfolio
- 14.7. Enzynomics
- 14.7.1. Company Overview
- 14.7.2. mRNA Synthesis Kits Portfolio
15. PARTNERSHIPS AND COLLABORATIONS
- 15.1. Partnership Models
- 15.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
- 15.1.1. Analysis by Year of Partnership
- 15.1.2. Analysis by Type of Partnership
- 15.1.3. Analysis by Year and Type of Partnership
- 15.1.4. Analysis by Type of Product
- 15.1.5. Analysis by Type of Partner
- 15.1.6. Most Active Players: Analysis by Number of Partnerships
- 15.1.7. Analysis by Geography
- 15.1.7.1. Intracontinental and Intercontinental Deals
- 15.1.7.2. Local and International Deals
16. LIKELY PARTNER ANALYSIS
- 16.1. Methodology and Key Parameters
- 16.2. Scoring Criteria
- 16.3. mRNA Drug Developers: Likely Partners based in North America
- 16.3.1. mRNA Drug Developers: Most Likely Partners based in North America
- 16.4. mRNA Drug Developers: Likely Partners based in Europe
- 16.4.1. mRNA Drug Developers: Most Likely Partners based in Europe
- 16.5. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
- 16.5.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World
17. BIG PHARMA INITIATIVES
- 17.1. Analysis Methodology
- 17.2. Scoring Criteria
- 17.3. Big Pharma Players: mRNA- focused Initiatives
- 17.4. Competitive Benchmarking of Big Pharma Players
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
- 18.1. Chapter Overview
- 18.2. Market Drivers
- 18.3. Market Restraints
- 18.4. Market Opportunities
- 18.5. Market Challenges
19. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET
- 19.1. Chapter Overview
- 19.2. Key Assumptions and Forecast Methodology
- 19.3. Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
- 19.3.1. Scenario Analysis
- 19.4. Key Market Segmentations
20. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT
- 20.1. Chapter Overview
- 20.2. Key Assumptions and Forecast Methodology
- 20.3. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
- 20.3.1. mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035 (USD Billion)
- 20.3.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035 (USD Billion)
21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA
- 21.1. Chapter Overview
- 21.2. Key Assumptions and Forecast Methodology
- 21.3. mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
- 21.3.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
- 21.3.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)
22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA
- 22.1. Chapter Overview
- 22.2. Key Assumptions and Forecast Methodology
- 22.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2023 and 2035
- 22.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
- 22.3.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
- 22.3.3 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)
23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
- 23.1. Chapter Overview
- 23.2. Key Assumptions and Forecast Methodology
- 23.3. mRNA Synthesis and Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2024 and 2035
- 23.3.1 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
- 23.3.2. mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
- 23.3.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
- 23.3.4. mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
- 23.3.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
- 23.3.6. mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035, USD Billion
24. EXECUTIVE INSIGHTS
- 24.1. Chapter Overview
- 24.2. Canvax
- 24.2.1. Company Snapshot
- 24.2.2. Interview Transcript: Bernardo Jose Gomez Fernandez, Business Development Manager
- 24.3. GC Pharma
- 24.3.1. Company Snapshot
- 24.3.2. Interview Transcript: Jaehoon Moon, Team Leader
- 24.4 Tebubio
- 24.4.1. Company Snapshot
- 24.4.2. Interview Transcript: Jean-Francois, Chief Commercial Officer
25. APPENDIX 1: TABULATED DATA
26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
Product Code: RA100401
List of Tables
- Table 6.1 List of mRNA Custom Synthesis Service Providers
- Table 6.2 mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
- Table 6.3 mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity
- Table 8.1 Aldevron: mRNA Custom Synthesis Service Portfolio
- Table 8.2 TriLink Biotechnologies: mRNA Custom Synthesis Service Portfolio
- Table 8.3 etheRNA: mRNA Custom Synthesis Service Portfolio
- Table 8.4 Biomay: mRNA Custom Synthesis Service Portfolio
- Table 8.5 GenScript: mRNA Custom Synthesis Service Portfolio
- Table 8.6 Aurigene Pharmaceutical Services: mRNA Custom Synthesis Service Portfolio
- Table 9.1 List of mRNA Contract Manufacturing Service Providers
- Table 11.1 Eurogentec: mRNA Contract Manufacturing Service Portfolio
- Table 11.2 Wuxi Biologics: mRNA Contract Manufacturing Service Portfolio
- Table 11.3 Merck: mRNA Contract Manufacturing Service Portfolio
- Table 11.4 ST Pharm: mRNA Contract Manufacturing Service Portfolio
- Table 11.5 Vernal Biosciences: mRNA Contract Manufacturing Service Portfolio
- Table 11.6 Curia: mRNA Contract Manufacturing Service Portfolio
- Table 12.1 List of mRNA Synthesis Kits
- Table 12.2 List of mRNA Synthesis Kit Providers
- Table 14.1 Jena Biosciences: mRNA Synthesis Kits Portfolio
- Table 14.2 APExBIO: mRNA Synthesis Kits Portfolio
- Table 14.3 ThermoFisher Scientific: mRNA Synthesis Kits Portfolio
- Table 14.4 CELLSCRIPT: mRNA Synthesis Kits Portfolio
- Table 14.5 New England Biolabs: mRNA Synthesis Kits Portfolio
- Table 14.6 Enzynomics: mRNA Synthesis Kits Portfolio
- Table 15.1 mRNA Synthesis and Manufacturing Services: List of Partnerships and Collaborations, since 2019
- Table 17.1 Big Pharma Players: List of mRNA Focused Initiatives, since 2019
- Table 25.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
- Table 25.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
- Table 25.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
- Table 25.4 mRNA Custom Synthesis Service Providers: Distribution by Type of Service Offered
- Table 25.5 mRNA Custom Synthesis Service Providers: Distribution by Starting Material
- Table 25.6 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
- Table 25.7 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method
- Table 25.8 mRNA Custom Synthesis Service Providers: Distribution by Application Area
- Table 25.9 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation
- Table 25.10 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
- Table 25.11 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
- Table 25.12 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
- Table 25.13 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
- Table 25.14 mRNA Contract Manufacturing Service Providers: Distribution by Type of Additional Services
- Table 25.15 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product Manufactured
- Table 25.16 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation
- Table 25.17 mRNA Synthesis Kits: Distribution by Kit Components
- Table 25.18 mRNA Synthesis Kits: Distribution by Type of Enzymes
- Table 25.19 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
- Table 25.20 mRNA Synthesis Kits: Distribution by mRNA Component Modified
- Table 25.21 mRNA Synthesis Kits: Distribution by Number of Reactions
- Table 25.22 mRNA Synthesis Kits: Distribution by Yield per Reaction
- Table 25.23 mRNA Synthesis Kits: Distribution by Reaction Run-time
- Table 25.24 mRNA Synthesis Kits: Distribution by Price of Kits
- Table 25.25 Most Active Players: Distribution by Number of Kits Offered
- Table 25.26 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
- Table 25.27 mRNA Synthesis Kit Providers: Distribution by Company Size
- Table 25.28 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
- Table 25.29 Partnerships and Collaborations: Distribution by Year of Partnership
- Table 25.30 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 25.31 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Table 25.32 Partnerships and Collaborations: Distribution by Type of Product (Broad)
- Table 25.33 Partnerships and Collaborations: Distribution by Type of Product (Specific)
- Table 25.34 Partnerships and Collaborations: Distribution by Type of Partner
- Table 25.35 Most Active Players: Distribution by Number of Partnerships
- Table 25.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
- Table 25.37 Partnerships and Collaborations: Local and International Deals
- Table 25.38 Global mRNA Synthesis and Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Billion)
- Table 25.39 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035) (Conservative Scenario) (USD Billion)
- Table 25.40 Global mRNA Synthesis and Manufacturing Market, Forecasted Estimates (till 2035) (Optimistic Scenario) (USD Billion)
- Table 25.41 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024, and 2035
- Table 25.42 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), till 2035 (USD Billion)
- Table 25.43 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs) till 2035 (USD Billion)
- Table 25.44 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024, and 2035
- Table 25.45 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
- Table 25.46 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)
- Table 25.47 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2024 and 2035
- Table 25.48 mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
- Table 25.49 mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
- Table 25.50 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)
- Table 25.51 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2021, 2024 and 2035
- Table 25.52 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
- Table 25.53 mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
- Table 25.54 mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
- Table 25.55 mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
- Table 25.56 mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
- Table 25.57 mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035 (USD Billion)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.